Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults

American Journal of Health-System Pharmacy

Volumn 54, Issue 10, 1997, Pages 1172-1176

  Boike, Steven C ^a   Ilson, Bernard ^a   Zariffa, Névine ^b   Jorkasky, Diane K ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c CPD ^*

Author keywords

Antiemetics; Drug administration rates; Drug administration routes; Drug comparisons; Granisetron hydrochloride; Injections; Ondansetron hydrochloride; Toxicity

Indexed keywords

ANTIEMETIC AGENT; GRANISETRON; ONDANSETRON; PLACEBO; SEROTONIN 3 ANTAGONIST;

ADULT; ARTICLE; BLOOD PRESSURE; BOLUS INJECTION; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE;

EID: 0030979242     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.10.1172     Document Type: Article

References (17)

1. Kytril package insert. Philadelphia: SmithKline Beecham Pharmaceuticals; 1994 Jun.
2. Zofran package insert. Research Triangle Park, NC: Cerenex Pharmaceuticals; 1993 Jan.
3. Bremer K. A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy. Eur J Cancer. 1992; 28A(suppl 6/7):1018-22.
4. Gralla RJ, for the Granisetron Study Group. The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. J Cancer Res Clin Oncol. 1993; 119:555-9.
5. Sledge GW, Einhorn LH, Nagy C et al. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer. 1992; 70:2524-8.
6. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomised study. Eur J Cancer. 1993; 29A:1669-72.
7. Noble A, Bremer K, Goedhals L et al. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer. 1994; 30A:1083-8.
8. Bazett HR. An analysis of the time relations of electrocardiograms. Heart. 1920; 7:353-70.
9. Azzaro AJ, Ward HE. Drugs used in mood disorders. In: Craig CR, Stitzel RE, eds. Modern pharmacology. 4th ed. Boston: Little, Brown; 1994:401.
10. Morganroth J, Brozovich FV, McDonald JT et al. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol. 1991; 67:774-6.
11. 3 antagonist. Eur J Cancer. 1990; 26(suppl 1):S12-5.
12. 3 antagonists, ondansetron and granisetron in feline ventricular myocytes. Br J Pharmacol. 1994; 113:527-35.
13. 3 receptor antagonists, in anesthetized dogs. Drug Dev Res. 1991; 24:277-84.
14. Hunt TL, Cramer M, Shah A et al. A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol. 1995; 35:705-12.
15. Baltzer L, Pisters KMW, Kris MG et al. High dose ondansetron plus dexamethasone for the prevention of nausea and vomiting with multiple day cisplatin chemotherapy. Proc Am Soc Clin Oncol. 1993; 12:462. Abstract.
16. Kris MG, Grunberg SM, Gralla RJ et al. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol. 1994; 12:1045-9.
17. Watanabe H, Hasegawa A, Shinozaki T et al. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol. 1995; 35:278-82.